Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Scilex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NeuroBiogen, Scilex Partner for Global KDS2010 Licensing in Phase 2 Diseases
Details : NeuroBiogen grant Scilex an exclusive worldwide license to the KDS2010 drug to develop and commercialize in metabolic diseases (including obesity and type 2 diabetes) and neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : Tisolagiline
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Scilex Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement